# What Instagram Leaves Out

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/what-instagram-leaves-out

> Researchers compared semaglutide posts across five platforms against what the STEP trials recorded. The most useful finding is an omission: the drug's most common side effects were absent from Instagram.

## Key points

- Semaglutide's very common gut effects were not mentioned on Instagram at all.
- Cost, a leading reason people stop, was barely covered, and so were supply shortages.
- Posts under #ozempic advertised products that did not contain semaglutide.
- YouTube rated most reputable, Instagram least.
- A content analysis, not a measurement, so we do not convert its wording into percentages.
- The 'Medicinal Products Act' cited is GERMAN law, not a US statute.

Researchers collected semaglutide posts from Instagram, TikTok, X, Facebook and YouTube and compared what they said against what [the STEP trials](https://glpwatchdog.org/research/lists/top-semaglutide-weight-loss-studies) recorded.[1] The study’s most useful finding is an omission rather than a false claim: the gastrointestinal effects that trouble most people who take this drug **were not mentioned on Instagram at all**.

## What was missing

Misinformation is usually imagined as false statements, things a careful reader could catch. The pattern this analysis describes is harder to defend against: an account of a drug that is accurate as far as it goes, with the uncomfortable parts left out.

- **Side effects.** Nausea, vomiting, constipation and diarrhea are the most common experiences on this drug and appear in every label. On Instagram, the analysis found them unmentioned.
- **Cost.** Barely covered, if at all, despite being a leading reason people stop.[2]
- **Supply shortages.** Barely covered either, in a period when they were a defining feature of getting the drug.
- **Indication.** Semaglutide was presented almost exclusively as a weight-loss drug, with its diabetes indication largely absent.

> On Instagram, the analysis found nausea, vomiting, constipation and diarrhea unmentioned.

The authors also report common misrepresentation of how the drug works, what it is for, its adverse effects and its interactions. Those are ordinary errors. The absences are the more consequential problem, because a reader cannot fact-check a topic that never came up.

## Who is doing the explaining

On Instagram and TikTok, most of the content creators were women taking semaglutide themselves, without medical training. Firsthand accounts of living with a treatment have real value, and people share them for good reasons.

What a personal account cannot do is describe the range. Someone posting has one experience of the drug; the label describes a distribution. If the people posting happen to be the ones who tolerated it (and those are the people still taking it, and therefore still posting), the aggregate picture skews without anyone saying anything untrue.

Across platforms, the analysis rated YouTube the most reputable source of medical information and Instagram the least.

## The part that overlaps with what we track

> **Some posts under the #ozempic hashtag advertised products that did not contain semaglutide.** That is the same phenomenon this register documents on the seller side: a recognized drug name used as a category label for something else. If you found a product through a hashtag, the hashtag is not a statement about what is in it.

The authors also identify violations of the Medicinal Products Act. That is **German pharmaceutical law**, in a German-published analysis. It is not a US statute, and nothing in this paper represents a finding by a US regulator.

Finally, the authors judge that weight-loss result videos have a high probability of having been modified with AI. [Before-and-after imagery](https://glpwatchdog.org/research/semaglutide-before-and-after) is easy to generate and impossible for a viewer to verify.

## How much weight to put on this

This is a content analysis, not a measurement. Phrases like *very common* and *barely covered* are the authors’ characterizations of the sample they gathered, and the published abstract does not give a sampling frame or counts. We do not convert them into percentages, because percentages would imply a precision the study does not claim.

Within that limit the direction is credible and matches what anyone who has looked at these platforms would expect. The most specific, checkable observation is that a drug’s most common adverse effects were absent from one platform’s coverage of it.

For what the trials record about side effects and how long they last, see [how long GLP-1 side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last). For the constipation nobody posts about, [what actually works](https://glpwatchdog.org/research/glp1-constipation-what-works).

## Frequently asked questions

### Is social media a reliable source on semaglutide?

This analysis found misrepresentation of the drug's mechanism, indication, adverse effects and interactions to be common across platforms, rated YouTube the most reputable and Instagram the least, and found the drug's very common gastrointestinal effects unmentioned on Instagram.

### What gets left out most?

Side effects, cost and supply shortages. The first is the drug's most common experience, cost is a leading reason people stop, and all three were largely or entirely absent.

### Why does an omission matter more than a false claim?

Because a reader can check a claim and cannot check a topic that never came up. An account that is accurate as far as it goes, with the uncomfortable parts missing, leaves someone confident and misinformed at the same time.

### Are products sold under the #ozempic hashtag actually semaglutide?

Not always. The analysis found posts under that hashtag advertising products that did not contain semaglutide. A hashtag is a category label, not a statement about contents.

### Were laws being broken?

The authors identified violations of the Medicinal Products Act, which is German pharmaceutical law. This was a German-published analysis, and nothing in it represents a finding by a US regulator.

## References

1. Propfe LE, Seifert R. Misrepresentation of semaglutide in social media. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. PMID: 40682686. https://pubmed.ncbi.nlm.nih.gov/40682686/
2. Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity. 2025. PMID: 41039650. https://pubmed.ncbi.nlm.nih.gov/41039650/

---

Cite as: GLP Watchdog, Nora Bissett, "What Instagram Leaves Out", published 2026-08-20, updated 2026-11-01. https://glpwatchdog.org/research/what-instagram-leaves-out

Canonical HTML page: https://glpwatchdog.org/research/what-instagram-leaves-out

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
